ERBB2 and breast cancer: About 60% of BC cases with HER2- metastatic expression exhibit low levels of HER2, defined as an immunohistochemical (IHC) score of 1+ or 2+ IHC score combined with a negative in situ hybridization result (ISH) [7, 8].